NCT06646978View on ClinicalTrials.gov

Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

Enrolling by invitationOBSERVATIONAL

Enrollment

787

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Chronic Myeloid Leukemia (CML)

Interventions

DRUG

Imatinib (STI571)

Imatinib-based regimen

Trial Locations (1)

86021

CHU de Poitiers, Poitiers

All Listed Sponsors

lead

Poitiers University Hospital

OTHER